Market Report

20th April 2018 at 5:06 pm

UK and European equities finished trading relatively flat, as investors digested a fresh batch of corporate earnings, while keeping an eye on international markets.

US stocks slipped as a decline in Apple pushed the technology sector lower. A rise in interest rates also kept a lid on equities.

The euro weakened below $1.23 and is poised for its biggest weekly drop in two months as investors trimmed record high bets before a European Central Bank meeting next week where policymakers are largely expected to signal no change in policy.

Oil prices stayed near three-year highs reached earlier this week, with ongoing OPEC-led supply cuts and strong demand gradually drawing down excess supplies.

Gold prices eased and were on track to end the week lower as the dollar advanced on expectations of higher interest rates and the view that global political and security risks were easing.

In case you missed the company news this morning, Allergan has pulled out of the pursuit for Shire only hours after saying it was pondering a possible takeover offer. The botox-maker confirmed in a statement on Friday morning that it “does not intend to make an offer for Shire”.

High performance components and sub-systems company Meggitt has secured a long-term agreement with Solar Turbines, it announced on Friday. The company said that under the five-year agreement, which included aftermarket support, Meggitt Control Systems would continue to supply electric valves and actuators for multiple engine programmes. It did not disclose the financial value of the deal.

Royal Mail said that its chief executive officer Moya Greene will retire in September after more than eight years in the role. Rico Back will assume the role of group CEO and join the board on 1 June, following the announcement of the 2017-18 results.

Indivior has filed a new drug submission (NDS) with Health Canada’s Therapeutic Drugs Directorate, it announced on Friday, for its ‘SUBLOCADE’ (buprenorphine extended-release) injection, for subcutaneous use for the treatment of moderate-to-severe opioid use disorder (OUD), as part of a complete treatment plan to include counselling and psychosocial support. The drugmaker said Health Canada had granted Priority Review status for SUBLOCADE on 6 April, and if approved, the treatment would be marketed by Indivior Canada.



At the close
FTSE 100 7,368 +0.54%
FTSE 250 20,220 +0.37%
DAX 12,540 (-0.21%)

At 16:59
Dow Jones 24,496 (-0.68%)
S&P 500 2,675 (-0.67%)
NASDAQ 7,166 (-0.99%)


Fixed Income
UK 10-YR YIELD 1.497 (-0.11%)


Exchange Rates
GBP/USD 1.403
GBP/EUR 1.142


Gold $1,337 (-0.47%)
Brent $73.690 +0.16%